Hematology News

Variations in donor platelet function did not affect the outcome of prophylactic transfusions among patients with hematologic disorders, according to a semi-randomized, double-blind study published in Blood.

Researchers, patients, policymakers, payer representatives and government agencies are working together to seek consensus on a core set of evaluation outcomes for hemophilia treatment.

Transfusing red blood cells stored longer than 35 days did not increase risk for in-hospital death compared with fresh blood, according to a secondary analysis of the randomized controlled INFORM trial.

The FDA has granted breakthrough therapy designation to four hematology/oncology agents.

A randomized phase 3 trial designed to assess emicizumab-kxwh for adults and adolescents with hemophilia A without factor VIII inhibitors met its primary endpoint, according to the agent’s manufacturer.

The FDA today approved emicizumab-kxwh to prevent or reduce the frequency of bleeding episodes among patients with hemophilia A who have developed factor VIII inhibitors.

Delayed cord clamping did not lower the incidence of death or major morbidity at 36 weeks gestation compared with immediate cord clamping among preterm infants, according to data published in The New England Journal of Medicine.

The FDA expanded the indication for ferric citrate tablets to include the treatment of iron deficiency anemia among adult patients with chronic kidney disease who are not on dialysis.

The FDA today cleared the XW-100 Automated Hematology Analyzer for use in patients aged at least 2 years who require a whole blood cell count and white blood cell differential.

The FDA expanded approval of vemurafenib to include certain adults with BRAF V600-mutated Erdheim-Chester disease.